Trial Profile
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 11 Dec 2023 Results assessing the efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy , published in the Oncologist
- 03 Aug 2021 Primary endpoint (Change from baseline in daily average pain intensity in index bone metastasis cancer pain site) has been met, according to an Eli Lilly and Company media release.
- 28 Jul 2021 Results published in Pfizer Media Release.